5th Annual MarketsandMarkets

Bioprocessing of Biotherapeutics-UK,EU & APAC-Virtual (Time zone- GMT)

20th - 21st May 2021

After the successful foureditions of Bioprocessing of Cell therapies, coming up with 5th Annual of Bioprocessing of Biotherapeutics brings together leading bioprocessing scientists to share day-to-day challenges and practical solutions for the development, manufacture and quality of protein expressions, cell, and gene therapies.

The virtual event will present detailed case studies and interactive discussions in cell culture, scale-up, continuous processing, recovery, purification, process and product characterization, and formulation.

WHAT TO EXPECT

  • Cell culture and bioproduction
  • Supply of lentiviral viral vectors
  • Cell therapy manufacturing
  • Close manufacturing practices
  • Car-T manufacturing
  • Automation & digitization
  • Inventory supply chain logistics
  • Bioreactor process: Autologous-single use manufacturing

VPs, heads, directors, managers, leaders, engineers, scientists, working in 

  • Cell Culture
  • Cell Therapy
  • Upstream Processing
  • Stem Cell therapy
  • Process Development
  • Bioprocessing
  • Downstream Processing
  • Quality Control
  • Bioengineering
  • Downstream Processing
  • Quality Control
  • Bioengineering
  • Translational Sciences
  • Scale-up/out
  • Bioprocess development

CONFERENCE AGENDA

Online registrations

08:15 - 08:45

Opening note by MarketsandMarkets

08:45 - 08:55

Opening remarks by Chairperson

08:55 - 09:00

CELL CULTURE & BIOPRODUCTION

Process Design for AAV-based Gene & Cell Therapy Vectors towards Commercialization

Barbara Kraus

Barbara Kraus, Head of Gene Therapy Process Development, Takeda

09:00 - 09:30

Developing a clinical grade manufacture of CYAD-101, a non-gene edited allogeneic NKG2D-based CAR T cell therapy for the treatment of solid malignancies

Emilie Gauthy

Emilie Gauthy, R&D Manager CMC and Process Development, Celyad

09:30 - 10:00

Introducing Stem Cell-Specific Dosing for Better Stem Cell and Gene Therapies

James L. Sherley

James L. Sherley, Founder & CEO, Asymmetrex LLC

10:00 - 10:30

UPSTREAM BIOPROCESSING & MANUFACTURING

Understanding the Regulatory and practical benefits of clonally-derived workflows

Duncan Borthwick

Duncan Borthwick, Global Marketing Manager, Solentim

10:30 - 11:00

Networking break & one on one meeting

11:00 - 11:20

Automation and digitalization of cell therapy manufacturing

Hemant Dhamne

Hemant Dhamne , Head of Vector and CAR-T Cell Processing, Immuneel Therapeutics Pvt Ltd

11:20 - 11:50

A new single-cell cloning and imaging platform and scale-down bioreactors for generating high producer cell lines with >99.99% monoclonality

Elly Sinkala

Elly Sinkala, Lead Application Scientist, Cytena

11:50 - 12:20

Developing the world’s first triple antigen Virus Like Particle (VLP) against SARS CoV-2 virus, and oral delivery

Prabuddha Kundu

Prabuddha Kundu, Co-founder & Managing Director,  Premas Biotech

12:20 - 12:50

Closing Remarks

13:20 - 13:25

End of Day 1

13:25 - 13:25

Online registrations

08:15 - 08:45

Opening note by MarketsandMarkets

08:45 - 08:55

Opening remarks by Chairperson

Stefano Baila

Stefano Baila, Director of Operations & Business Development, Anemocyte

08:55 - 09:00

DOWNSTREAM BIOPROCESSING & MANUFACTURING

Stem Cells & Regenerative Medicine : An Emerging Opportunity for Indian Life Sciences & Health-Care Ecosystem

Vishal Gandhi

Vishal Gandhi, Founder & CEO, Biorx Venture Advisors Pvt. Ltd

09:00 - 09:20

About the hurdles of cell therapy manufacturing for a clinical trial

Jenny Prange

Jenny Prange, Chief Scientific Officer, MUVON Therapeutics AG

09:20 - 09:50

Stem cell & Regenerative Medicine in Infertilty

Prabhu Chandra Mishra

Prabhu Chandra Mishra, Head, Department of Regenerative Medicine, Stemmax Research & Therapeutics Pvt Ltd

09:50 - 10:20

Networking & One on one meeting

10:20 - 10:45

ANALYTICS, REGULATORY & SUPPLY CHAIN

Cell therapy standardisation:

Elsa Branches

Elsa Branches, Interim Head-Advanced Therapies, Medicines and Healthcare Products Regulatory Agency

10:45 - 11:15

Overcoming the bottle neck of autologous manufacturing by adaptive culturing and sensor based automation

Ohad Karneili

Ohad Karneili, Founder & CEO, Adva Biotechnology

11:15 - 11:45

Plasmids and other underestimated challenges and opportunities for cell gene-modification

Stefano Baila

Stefano Baila, Director of Operations & Business Development, Anemocyte

11:45 - 12:15

End to end logistics and inventory management of biotherapeutics

Fabio D'Agostino

Fabio D'Agostino, Venture Partner-Cell Gene Therapy expert, Claris Ventures SGR SpA

12:15 - 12:45

Closing Remarks

12:45 - 12:50

End of Conference

12:50 - 12:50

SPEAKERS

Stefano Baila

Stefano Baila

Director of Operations & Business Development, Anemocyte

Ohad Karneili

Ohad Karneili

Founder & CEO, Adva Biotechnology

Hemant Dhamne

Hemant Dhamne

Head of Vector and CAR-T Cell Processing, Immuneel Therapeutics Pvt Ltd

Barbara Kraus

Barbara Kraus

Head of Gene Therapy Process Development, Takeda

Emilie Gauthy

Emilie Gauthy

R&D Manager CMC and Process Development, Celyad

James L. Sherley

James L. Sherley

Founder & CEO, Asymmetrex LLC

Vishal Gandhi

Vishal Gandhi

Founder & CEO, Biorx Venture Advisors Pvt. Ltd

Fabio D'Agostino

Fabio D'Agostino

Venture Partner-Cell Gene Therapy expert, Claris Ventures SGR SpA

Prabhu Chandra Mishra

Prabhu Chandra Mishra

Head, Department of Regenerative Medicine, Stemmax Research & Therapeutics Pvt Ltd

Duncan Borthwick

Duncan Borthwick

Global Marketing Manager, Solentim

John Lamb

John Lamb

Applications Scientist, Namocell

Elsa Abranches

Elsa Abranches

Acting Head, Division of Advanced Therapies Director, UK Stem Cell Bank

Prabuddha Kundu

Prabuddha Kundu

Co-founder & Managing Director,  Premas Biotech

SPONSORS

PARTNERS